Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Summary

This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21 patients) will be enrolled (including those enrolled in the safety lead-in portion).

Timeline

Start

2022-12-21

Primary completion

2025-07-23

Completion

2025-07-23

Outcome

Outcome not reported

Stopped (Enrollment): “Closed to accrual due to low probability of successful outcomes”

Drugs

Indications